Before Header Navigation - Desktop

  • For Healthcare Professionals
    • Allurion Partner Program
    • Virtual Care Suite
    • Allurion Insights Login
    • 4C Hub & 4C Learning Lab
United States
Choose your country or region in order to display more relevant content.
Select
Select
Albania
Algérie
Argentina
Australia
Bahrain
Belgique
België
Bolivia
Brasil
Canada
Canada (Français)
Chile
China
Colombia
Costa Rica
Curacao
Cyprus
Czech Republic
Danmark
Deutschland
Ecuador
Egypt
El Salvador
España
Estonia
France
Greece
Guatemala
Honduras
Hong Kong
Hungary
Indonesia
Iran
Ireland
Israel
Italia
Japan
Kenya
Korea
Kuwait
Latvia
Lebanon
Lithuania
Luxemburg
Malaysia
Maroc
Mexico
Moldova
Nederland
New Zealand
Norway
Oman
Panama
Peru
Poland
Portugal
Qatar
República Dominicana
Romania
Russia
Saudi Arabia
Schweiz
Singapore
Slovakia
Slovenia
South Africa
Suisse
Suomi
Sweden
Taiwan
Thailand
Tunisie
Türkiye
UAE
United Kingdom
United States
Uruguay
Venezuela
Vietnam
Österreich
الأردن
الإمارات العربية المتحدة
البحرين
الجزائر
العراق
الكويت
المغرب
المملكة العربية السعودية
تونس
دولة قطر
سلطنة عمان
لبنان
مصر
Other country or region
Continue
Home
Menu

V2 Main navigation

  • Get Started
    • Get started
    • ELIGIBILITY CHECK
  • How It Works
    • How it works
    • The Technology
  • Eligibility Check
  • Patient waiting list
  • For Healthcare Professionals
    • ALLURION PARTNER PROGRAM
    • VIRTUAL CARE SUITE
    • ALLURION INSIGHTS LOGIN
    • 4C HUB & 4C LEARNING LAB
Ip Address
216.73.216.111
Country
United States of America
Country Code
US

Site map

Menu
Close

Main navigation - US

  • Home
  • About Allurion
  • Meet the Team
  • Our Story
  • Careers
  • For Healthcare Professionals
    • ALLURION PARTNER PROGRAM
    • VIRTUAL CARE SUITE
    • ALLURION INSIGHTS LOGIN
    • 4C HUB & 4C LEARNING LAB

References

  • *In rare cases, the Allurion Balloon may require endoscopic or surgical intervention for removal.
  1. The AUDACITY Study. 48-week LOCF results in mITT population. Data on File (2025)
  2. This information is extracted from the instructions for use of the Allurion Gastric Balloon System. Version number CS137- 02-ENG (to be updated with US IFU). If you have any questions regarding this document, please consult your doctor.

     

    • Studies conducted and data collected outside the United States:
  3. Ienca R, Al Jarallah M, Caballero A, et al. The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients. Obes Surg. 2020;30(9):3354-3362. doi:10.1007/s11695-020-04539-8
  4. Dejeu D, Dejeu P, Bradea P, Muresan A, Dejeu V. Evaluating Weight Loss Efficacy in Obesity Treatment with Allurion's Ingestible Gastric Balloon: A Retrospective Study Utilizing the Scale App Health Tracker. Clin Pract. 2024;14(3):765-778. Published 2024 May 6. doi:10.3390/clinpract14030061.
  5. Caballero A, Giardiello C, Schiano Di Cola R, Rosa M, Juneja G, Pagan A, Murcia S, Formiga A, Freda A, Ienca R. Weight Loss Maintenance 1 Year after the Swallowable Gastric Balloon: Results from an International Multicenter Study. Obes Surg. 2025 Jul 17. doi: 10.1007/s11695 -025 -08074 - 2. Epub ahead of print. PMID: 40676353.
  6. The app was not part of the Audacity study, however it has been an integral part of the studies performed outside of US and is provided as part of Allurion Gastric Balloon System to patients outside of US.

Footer

  • Meet The Team
  • Our Story
  • Privacy Policy
  • Safety
  • Terms of Use
  • Investors
  • For Healthcare Professionals
© Allurion 2026

Social links

  • Facebook
  • YouTube
  • Instagram
  • LinkedIn

click me

Chat with Ally